228
Views
2
CrossRef citations to date
0
Altmetric
Letter to the Editor

The value of extended inflammatory parameters obtained on Sysmex XN-1000 haematology analyser as early laboratory indicators of COVID-19

, , , , &
Pages 257-259 | Received 09 Oct 2021, Accepted 20 Mar 2022, Published online: 04 Apr 2022

References

  • Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424–432.
  • Bergamaschi L, Mescia F, Turner L, et al. Early immune pathology and persistent dysregulation characterise severe COVID-19. medRxiv. 2021.
  • Urrechaga E, Mugertza G, Fernández M, et al. Leukocyte differential and reactive lymphocyte counts from sysmex XN analyzer in the evaluation of SARS-CoV-2 infection. Scand J Clin Lab Invest. 2021;81(5):394–400.
  • Lapić I, Brenčić T, Rogić D, et al. Cell population data: could a routine hematology analyzer aid in the differential diagnosis of COVID-19? Int J Lab Hematol. 2021;43(2):e64–e67.
  • Henry BM, Santos de Oliveira MH, Benoit S, et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021–1028.
  • Meizlish ML, Pine AB, Bishai JD, et al. A neutrophil activation signature predicts critical illness and mortality in COVID-19. Blood Adv. 2021;5(5):1164–1177.
  • Urrechaga E, Ponga C, Fernández M, et al. Diagnostic potential of leukocyte differential and cell population data in prediction of COVID-19 among related viral and bacterial infections at emergency department. Clin Chem Lab Med. 2022. [Epub ahead of print]
  • Yip CYC, Yap ES, De Mel S, et al. Temporal changes in immune blood cell parameters in COVID-19 infection and recovery from severe infection. Br J Haematol. 2020;190(1):33–39.
  • Rolla R, Vidali M, Puricelli C, et al. Reduced activity of B lymphocytes, recognised by Sysmex XN-2000™ haematology analyser, predicts mortality in patients with coronavirus disease 2019. Int J Lab Hematol. 2021;43(1):e5–e8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.